Navigation Links
In prostate cancer prognosis, telomere length may matter
Date:9/26/2013

Like the plastic caps at the end of shoelaces, telomeres protect in their case the interior-gene containing parts of chromosomes that carry a cell's instructional material. Cancer cells are known to have short telomeres, but just how short they are from cancer cell to cancer cell may be a determining factor in a prostate cancer patient's prognosis, according to a study led by Johns Hopkins scientists.

"Doctors are looking for new ways to accurately predict prostate cancer patients' prognoses, because the current methods that use disease stage, Gleason score, and PSA are not perfect," says Alan Meeker, Ph.D., assistant professor of pathology at The Johns Hopkins University School of Medicine and its Kimmel Cancer Center. "Telomere shortening is common in cancer, but the degree of shortening varies from one cancer cell to another within each patient, and this variability may give us a better idea of how prostate cancers behave."

In the study, described in the October issue of Cancer Discovery, the scientists studied tissue samples from 596 men surgically treated for prostate cancer thought to be confined to the prostate and who were participants in a long-term follow-up study on men's health. Then, they used images of prostate cancer cells and nearby cells called stroma, which include smooth muscle and fibroblast cells, taken from surgery-tissue samples of each patient.

Meeker and his team used a technique they developed called telomere-specific fluorescent in situ hybridization (TELI-FISH) to measure telomere length in cancer and stromal cells. The technique uses fluorescent-labeled probes specific for particular locations in DNA, and is commonly used to detect or confirm gene or chromosome abnormalities. In the new study, a fluorescent probe specific for telomere regions was added to the cells, enabling the scientists to identify these specific chromosomal locations under a microscope and measure the level of fluorescence that corresponds to telomere length.

After determining telomere length for more than 40,000 cells among the samples, disease-pattern experts at Johns Hopkins then correlated telomere length measurements in the cancer and stromal cells with each patient's survival.

"Men who had a combination of more variable telomere length among cancer cells and shorter telomere length in stromal cells were more likely to develop metastatic disease and die sooner from their prostate cancer than other men," says Elizabeth Platz, Sc.D., M.P.H., professor of epidemiology at The Johns Hopkins Bloomberg School of Public Health and the Martin D. Abeloff Scholar in Cancer Prevention at the Johns Hopkins Kimmel Cancer Center.

In the group of 98 men with more variable telomere length in cancer cells and shorter telomeres in stromal cells, 20 died of their prostate cancer an average of 8.4 years after diagnosis. Accounting for standard prognostic factors, these men were 14 times more likely to die of their prostate cancer compared with another group of 98 men whose telomeres had less variable length among cancer cells and were longer in stromal cells. In this group, only one man died, and that was after 16.5 years.

"Our studies strongly suggest that the combination of telomere length in stromal cells and its variability among prostate cancer cells could be a marker for prostate cancer prognosis," says Platz.

Meeker and Platz are continuing to study additional groups of patients and are now using an automated fluorescence microscope and computer software to speed the collection of tissue images and extract telomere data.


'/>"/>

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine
Source:Eurekalert

Related medicine news :

1. Unstable chromosomes linked to less favorable response to RT and surgery in prostate cancer patients
2. ASTRO/AUA joint guideline for RT after prostatectomy highlighted at ASTRO Annual Meeting
3. Prostate Cancer Added to List of Diseases Eligible for Zadroga Act Coverage; Parker Waichman LLP Applauds Decision
4. Moffitt Cancer Center launches prostate cancer study focused on black men
5. Made Sick from Prostate Cancer Awareness and Screening
6. LUGPA: Ladies: Save That Special Man in Your Life by Encouraging a Prostate Test in September
7. CEO of Award-Winning SEO Services Company, 180Fusion, Scott Cohen Elected to Emcee 2013 Prostate Cancer Dinner Gala
8. Cleveland Clinic researcher finds genetic mutation in castration-resistant prostate cancer
9. Targeting aggressive prostate cancer
10. Prostate cancer screening: New data support watchful waiting
11. UCLA prostate cancer research program receives $11.6 million federal grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 07, 2016 , ... The Cliff Hart Agencies, a Michigan-based ... Dewitt, Williamston, East Lansing, Ann Arbor, and Farmington Hills, is announcing a regional ... tumor. , Jason Bauer and his family are longtime members of the Williamston ...
(Date:12/7/2016)... ... 2016 , ... AlignLife clinics nationwide are giving back to their communities by ... receive bountiful gifts wrapped tightly under a Christmas Tree. AlignLife hopes to spread ... world. , In exchange for generous donations, customers will receive a gift in return. ...
(Date:12/7/2016)... ... 07, 2016 , ... The Honolulu cosmetic and medical dermatology ... launched October 17, 2016, features comprehensive information regarding a wide range of dermatologic ... patients can discover the latest clinical dermatology treatments for medical skin concerns as ...
(Date:12/7/2016)... ... December 07, 2016 , ... 1105 Media’s Live ... the Folio: Marketing Awards competition. Live From won in the Use of Social ... and ultimately successful projects undertaken by the media industry’s most innovative marketing professionals. ...
(Date:12/7/2016)... , ... December 07, 2016 ... ... announced its newest portable bioelectronic medicine device WellnessPro Plus for consumers and ... substantially enhances the WellnessPro platform by expanding the treatment modalities available in ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Diplomat Pharmacy, Inc. (NYSE: DPLO) has launched Diplomat Specialty ... IV Infusion Professional, BioRx, MedPro Rx, and XAS Infusion Suites. ... diplomat.is/specialty-infusion .  ... Diplomat Specialty Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ... "As we continue to build on the work we have ...
(Date:12/7/2016)... , Dec. 7, 2016  Varian Medical Systems (NYSE: ... its previously announced plans to separate its Imaging Components ... a tax-free distribution to Varian stockholders of common stock ... that will hold the Imaging Components business.  As part ... executed by the end of January 2017, Varian will ...
(Date:12/7/2016)... , Dec. 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: ... will present a company overview at the BMO Capital Markets Prescriptions ... New York, NY . A live webcast of ... of the Ionis website.  The replay will be available within 48 ... ...
Breaking Medicine Technology: